Page last updated: 2024-11-11

cv 1808

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-phenylaminoadenosine: has coronary & cardiohemodynamic effects [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917803
CHEMBL ID1256672
CHEBI ID175603
SCHEMBL ID725689
MeSH IDM0087446

Synonyms (48)

Synonym
MLS002153318
CHEBI:175603
(2r,3r,4s,5r)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
gtpl420
(2r,3r,4s,5r)-2-[6-amino-2-(phenylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
cv-1808
(3r,4s,5r)-2-(6-amino-2-anilino-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-phenylaminoadenosine, >97%, solid
PDSP1_000996
PDSP1_001206
PDSP2_001190
PDSP2_000980
smr000326899
2-phenylaminoadenosine
MLS000860041
adenosine, 2-(phenylamino)-
cv 1808
NCGC00025270-02
NCGC00025270-03
53296-10-9
2-phenylamino adenosine
2-(phenylamino)ado (cv-1808)
2-[6-amino-2-(3-cyclohexyl-propylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol
bdbm82022
n6-phenylado
CHEMBL1256672 ,
cv1808
(2r,3r,4s,5r)-2-(6-amino-2-(phenylamino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
HMS2235F09
AKOS016004073
unii-k40i59g1ef
k40i59g1ef ,
adenosine, 2-phenylamino
SCHEMBL725689
(2s,3s,4r,5s)-2-(6-amino-2-(phenylamino)-9h-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
AC-27396
2-(6-amino-2-anilino-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
HMS3676D20
Q27076929
HMS3412D20
NCGC00025270-06
DTXSID70967878
2-(phenylamino)-adenosine
A848769
C15934
MS-25626
HY-103183
CS-0025221

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A moderate hypotension was induced by CV-1808, nifedipine, and nitroglycerin, while a significant reduction in cardiac function was seen after dosing with propranolol."( Effect of 2-phenylaminoadenosine (CV-1808) on ischemic ST-segment elevation in anesthetized dogs.
Fujiwara, S; Hirata, M; Imamoto, T; Kawazoe, K; Matsumoto, N; Tanabe, M,
)
0.13
" Dose-response curves demonstrated that each agonist produced a dose-related rise in IOP with the following rank order of potency: NECA > CV-1808 > > R-PIA = CGS-21680."( Characterization of ocular hypertension induced by adenosine agonists.
Crosson, CE; Gray, T, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency12.63630.01846.806014.1254AID624148; AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency8.91250.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency3.22670.004110.890331.5287AID493106; AID493107
USP1 protein, partialHomo sapiens (human)Potency0.50120.031637.5844354.8130AID743255
regulator of G-protein signaling 4Homo sapiens (human)Potency0.00530.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.19230.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency3.16230.794321.275750.1187AID624246
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)1.38000.00020.552110.0000AID31410
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.55560.00011.20929.9700AID1138017; AID31717; AID32025; AID32177; AID32503
Adenosine receptor A2aHomo sapiens (human)Ki0.07600.00001.06099.7920AID1874230
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)0.14500.00240.68169.0000AID33405
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.09620.00061.353610.0000AID33440; AID33574; AID33733
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.14500.00120.48289.0000AID33405
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.09680.00021.494010.0000AID1138013; AID33440; AID33574; AID33733
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)EC50 (µMol)0.01820.00030.708110.0000AID30507
Adenosine receptor A2aHomo sapiens (human)Kd0.00910.00020.47319.6000AID1874229
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)0.01820.00030.946110.0000AID30507
Adenosine receptor A1Cavia porcellus (domestic guinea pig)EC50 (µMol)12.58920.01261.93385.6234AID32148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC506.71100.00564.693226.6940AID588345
Adenosine receptor A1Rattus norvegicus (Norway rat)EC25 (µMol)0.00300.00300.01420.0350AID175310
Adenosine receptor A2bRattus norvegicus (Norway rat)EC25 (µMol)0.00300.00300.01420.0350AID175310
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.11900.00330.82929.6000AID33746
Adenosine receptor A2aRattus norvegicus (Norway rat)EC25 (µMol)0.00300.00300.01420.0350AID175310
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.11900.00330.82309.6000AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID31717Adenosine A1 receptor binding was measured in adenosine deaminase (ADA) pretreated rat cortical membranes using [3H]cyclohexyladenosine in the presence of 2-chloroadenosine1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID186581Heart rate was recorded as baseline prior to the drug administration in hypertensive rats at 3.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID224988Dose producing 30% decrease of blood pressure in anesthetized rats (SHR)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID186585Heart rate was recorded as change after 6 h of following oral dosing hypertensive rats at 0.3 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID186579Heart rate was recorded as baseline prior to the drug administration in hypertensive rats at 10 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID33733Inhibition of binding of [3H]NECA to adenosine A2 receptor of rat striatal membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID1874230Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as inhibition constant by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1138018Binding affinity to human recombinant adenosine A3 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID31410Concentration required for 50% inhibition of [3H]-CHA binding on rat brain adenosine A1 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID1138014Agonist activity at human recombinant adenosine receptor A2b by cAMP assay2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID232320Ratio of A1-receptor binding to that of A2-receptor binding1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID32645Selectivity against adenosine A1 to A2 receptors1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID186728Mean arterial pressure were recorded as baseline prior to the drug administration in hypertensive rats at 0.3 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID232472Selectivity ratio for A1 receptor to that of A2 receptor in vitro in rat tissues1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID32148Prolongation of the stimulus-QRS interval by 50% of the maximum response at the adenosine A1 receptor in langendorff guinea pig heart preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor.
AID33592Binding to Adenosine A2 receptor was measured in ADA-pretreated rat striatal membranes using [3H]-CGS- 216801990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID229799Ratio of Ki at adenosine A2 and A1 receptors1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID186718Heart rate was recorded as change after 6 h of following oral dosing hypertensive rats at 10 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID32639Ratio of IC50 values for A1 receptor binding to that of A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID175312Reduction of heart rate (A1 response) in isolated rat heart preparation1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID33575Binding affinity against adenosine A2 receptor in rat striatal membranes using [3H]NECA as radioligand1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID194223Change in heart rate was expressed in percent at at a dose 0.29 mg/kg iv in anesthetized rat1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID33440Binding affinity at adenosine A2 receptor from rat striatal membranes by [3H]NECA displacement.1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID33588Binding affinity towards adenosine A2 receptor on rat striatal membrane using [3H]NECA as radioligand1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1138013Binding affinity to rat recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID31866Binding affinity at adenosine A1 receptor from rat brain membranes by [3H]N6-cyclohexyladenosine displacement.1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID1874228Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as affinity off-rate by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID186715Heart rate was recorded as change after 6 hr of following oral dosing hypertensive rats at 1.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID33574Binding affinity against adenosine A2 receptor from rat striatum using [3H]NECA as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID234758Selectivity determined as Ratio of Ki(nM) of A1 adenosine receptor to the Ki(nM) of A2 adenosine receptor1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID228181Dose producing 10% decrease in heart rate of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID33405Concentration required for 50% inhibition of [3H]NECA binding on rat brain adenosine A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID186576Heart rate was recorded as baseline prior to the drug administration in hypertensive rats at 1.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID232382Ratio of EC50 stim-QRS (conduction block) and EC50 for vasodilation of coronary arteries1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor.
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID186574Heart rate was recorded as baseline prior to the drug administration in hypertensive rats at 0.3 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID175308Effective concentration required for 25% increase in heart rate in perfused working heart model was determined1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID186730Mean arterial pressure were recorded as baseline prior to the drug administration in hypertensive rats at 1.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID32195Binding affinity towards adenosine A1 receptor on rat whole brain membrane using [3H]N6-cyclohexyladenosine1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID32026Binding affinity against adenosine A1 receptor in rat brain membranes using [3H]CHA as radioligand1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID175307Effective concentration required for 25% increase in coronary flow(CF) in perfused working heart model was determined1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.
AID175310Enhancement of coronary flow (A2 response) in isolated rat heart preparation1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID1138017Binding affinity to rat recombinant adenosine A1 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID224981Dose producing 10% decrease of heart rate in anesthetized rats (SHR)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID32025Binding affinity against adenosine A1 receptor from rat brain membranes using [3H]cyclohexyladenosine as radioligand.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID1874229Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as dissociation constant by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID186744Mean arterial pressure were recorded as change after 6 hr of following oral dosing hypertensive rats at 3.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID186734Mean arterial pressure were recorded as baseline prior to the drug administration in hypertensive rats at 3.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID1874227Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as affinity on-rate by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID186740Mean arterial pressure were recorded as change after 6 hr of following oral dosing hypertensive rats at 1.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID231269Ratio of binding affinity against A2 and A1 receptors1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID30507Coronary arteries vasodilation at the adenosine A2 receptor in langendorff guinea pig heart preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor.
AID186720Heart rate was recorded as change after 6 hr of following oral dosing hypertensive rats at 3.0 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID186738Mean arterial pressure were recorded as change after 6 hr of following oral dosing hypertensive rats at 0.3 mg/kg dose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID228183Dose producing 30% decrease in blood pressure of anesthetized spontaneously hypertensive rats (SHR's)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.
AID17397425% reduction in blood pressure in the rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID32503Inhibition of binding of [3H]N6-cyclohexyladenosine to adenosine A1 receptor of rat whole brain membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1345618Human A2A receptor (Adenosine receptors)1999Biochemical pharmacology, Jan-01, Volume: 57, Issue:1
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
AID1345618Human A2A receptor (Adenosine receptors)1997British journal of pharmacology, Jun, Volume: 121, Issue:3
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (13.33)18.7374
1990's29 (48.33)18.2507
2000's5 (8.33)29.6817
2010's12 (20.00)24.3611
2020's6 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.70 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]